European Patent Office intends to grant a new patent for Isofol’s arfolitixorin
GOTHENBURG, Sweden, November 13 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the European Patent Office […]
Corporate Information
Isofol appoints nomination committee ahead of the Annual General Meeting 2026
GOTHENBURG, Sweden, November 4, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that
Isofol invites to an investor meeting on November 13, 2025
GOTHENBURG, Sweden, October 28, 2025 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) hereby invites investors and shareholders to an
Isofol participates in the ESMO cancer congress
GOTHENBURG, Sweden, October 16, 2025 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company will participate
Isofol’s clinical study with arfolitixorin reaches another important milestone
GOTHENBURG, Sweden, September 30, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has successfully
Isofol completes transfer of shares to Solasia Pharma following a successful rights issue
GOTHENBURG, Sweden, September 26, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the transfer of the
Isofol invites to a presentation of the interim report for the second quarter 2025
GOTHENBURG, Sweden, August 21, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites investors, analysts and media to
Isofol successfully completes pre-IND meeting with the FDA for arfolitixorin
GOTHENBURG, Sweden, July 16, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has successfully
Isofol completes first cohort in ongoing clinical study with arfolitixorin
GOTHENBURG, Sweden, June 12, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has completed
Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on 11 June 2025
GOTHENBURG, 11 June 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its extra ordinary general meeting today at